Tom Beveridge
Global Product Lead, Paltusotine for Carcinoid Syndrome

For individuals living with carcinoid syndrome (CS), a condition caused by neuroendocrine tumors (NETs), severe symptoms such as flushing, diarrhea and abdominal pain can significantly disrupt daily life. Despite the dedication of clinicians, researchers, and advocates, treatment options remain limited – both for controlling the symptoms of CS and addressing the underlying cancer that drives them.

At Crinetics, we are focused on bringing forward the next generation of treatments that are purposefully built to treat both NETs and CS. That belief has driven our clinical development of paltusotine, an investigational, oral, selective somatostatin receptor type 2 (SST2) agonist currently being studied for the treatment of carcinoid syndrome due to NETs.

CS is a complex disease that often requires long-term treatment strategies that balance therapeutic effectiveness with patients’ quality of life. Current standard-of-care therapies can be effective, but are frequently associated with treatment burdens related to their mode of administration. Our development of paltusotine, a once-daily oral therapy, is under development for CS to offer an alternative that maintains disease control while improving convenience and comfort. This approach draws on our deep expertise in G-protein coupled receptor (GPCR) biology, particularly the somatostatin signaling pathways that regulate hormone secretion and tumor growth.

Paltusotine is a nonpeptide small molecule in development for the treatment of CS. It is designed to mimic the effects of the natural hormone somatostatin, providing sustained activation of the SST2 receptor in a once-daily oral form. By targeting this pathway, paltusotine may help control the biochemical processes that drive CS symptoms and, as emerging evidence suggests, could also impact the underlying tumor activity.

Progress Highlighted at NANETS 2025
At this year’s North American Neuroendocrine Tumor Society (NANETS) Annual Meeting, we were proud to share one-year investigator-assessed progression-free survival data (PFS) from our Phase 2 study of paltusotine in carcinoid syndrome, which showed a PFS rate of 74% following one year of treatment. These findings underscore the promise of a selectively targeted somatostatin receptor agonist like paltusotine for people living with carcinoid syndrome. We also presented trial details from CAREFNDR, , in addition to details from a Phase 1/2 trial of investigative candidate CRN09682, our first-in-class nonpeptide drug conjugate (NDC) designed to selectively target somatostatin receptor 2 (SST2)-expressing tumors. Together, these investigational programs reflect Crinetics’ broader effort to translate scientific discovery into tangible progress for patients.

A Commitment to Scientific Progress and Patient Impact
Innovation in rare endocrine diseases requires persistence, collaboration, and deep respect for the patient experience. At Crinetics, we are committed to advancing endocrine science through rigorous clinical investigation and meaningful engagement with the communities we serve.

Our work in carcinoid syndrome is part of a broader mission: to harness our GPCR expertise to develop therapies that address the root biology of endocrine disorders, improve patient quality of life, and expand options for long-term disease management.

Looking Ahead
The path forward in NETs care will be shaped by continued scientific inquiry and shared dedication across the research community. As our studies progress, we remain focused on translating discovery into impact—bringing us closer to a future where people living with carcinoid syndrome can achieve better, more consistent control of their disease.